Related Experiment Video
Updated: Aug 10, 2026

Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography
Published on: March 30, 2022
Towards third generation matrix metalloproteinase inhibitors for cancer therapy
1CBCRA Program in Breast Cancer Metastasis, Department of Oral Biological & Medical Sciences, The UBC Centre for Blood Research, University of British Columbia, Vancouver, BC, Canada V6T 1Z3. chris.overall@ubc.ca
Abstract:
The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for validated MMP targets yet therapeutically spare MMP antitargets that are critical in host protection.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Tumor Microenvironment
Role of Matrix Metalloproteases in Degradation of ECM
A...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules

